© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
June 05, 2020
Denise Yardley, MD, sheds light on individualized treatment approaches and other key developments in HER2-positive breast cancer.
May 14, 2020
Joyce A. O'Shaughnessy, MD, sheds light on the current paradigm of HER2-positive breast cancer and the optimal role of neratinib in the early-stage and advanced settings.
April 24, 2020
Adam M. Brufsky, MD, PhD, highlightes the treatment landscape in HER2-positive breast cancer, remaining sequencing questions, and the growing utility of neratinib in the paradigm.